X4 Pharmaceuticals closes upsized $85M private placement for mavorixafor development and WHIM commercialization

X4 Pharmaceuticals, Inc

Closed private placement of 11,040,776 shares and 48,852,772 pre-funded warrants for gross proceeds of $85M.
Purchase price per pre-funded warrant is $1.419; exercise price is $0.001 per share; warrants have no expiration.
Offering upsized from $60M due to pre-existing investment right from one investor; led by Coastlands Capital with support from existing investors.
Net proceeds to be used for continued development of mavorixafor for chronic neutropenia and commercialization of WHIM.
Shares and underlying shares to be registered for resale via an SEC registration statement.

item 1.01item 3.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.